GSEA-assisted Gene Signatures Valid for Combinations of Prognostic Markers in PCNSL

Overview

Journal Sci Rep

Specialty Science

Date 2020 May 23

PMID 32439996

Citations 7

Authors

Yasuo Takashima

Momoko Hamano

Junya Fukai

Yasuo Iwadate

Koji Kajiwara

Tsutomu Kobayashi

Hiroaki Hondoh

Ryuya Yamanaka

Affiliations

Soon will be listed here.

Abstract

Primary central nervous system lymphoma (PCNSL) is a brain malignant non-Hodgkin's B-cell lymphoma. The standard treatments are high-dose methotrexate (MTX)-based chemotherapies and deferred whole brain radiotherapy. However, MTX resistance-dependent global expression and signaling pathway changes and their relationship with prognoses have not yet been elucidated. Here, we conducted a global expression analysis with next-generation sequencing and gene set enrichment analysis (GSEA) in MTX-resistant PCNSL cell lines (HKBML-MTX and TK-MTX) and PCNSL tissues. In rank scores, genes listed in HKBML-MTX and TK-MTX were enriched in PCNSL with poor prognoses. In fold changes, a part of differentially-expressed genes in PCNSL tissues were also detected in HKBML-MTX and TK-MTX cells; FOXD2-AS1 and MMP19 were commonly expressed in both HKBML-MTX and TK-MTX, FABP5 and CD70 were HKBML-MTX-specifically expressed, and CLCN2, HOXB9, INE1, and LRP5L were TK-MTX-specifically expressed, which may provide a combination of prognostic markers on MTX-sensitivities in PCNSL. Additionally, PCNSL subgroups, divided with hierarchical clustering and Kaplan-Meier methods, included twenty commonly expressed genes in both HKBML-MTX and TK-MTX, ten HKBML-MTX-specifically expressed genes, and two TK-MTX-specifically expressed genes. These results suggest that the GSEA-assisted gene signatures can provide a combination for prognostic markers in recurrent PCNSL with MTX resistances.

Citing Articles

Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.

Guo Z, Zhang X, Yang D, Hu Z, Wu J, Zhou W Sci Rep. 2024; 14(1):10348.

PMID: 38710798 PMC: 11074108. DOI: 10.1038/s41598-024-61175-3.

Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment.

Zhou L, Li Q, Xu J, Wang S, Song Z, Chen X Neurooncol Adv. 2023; 5(1):vdac181.

PMID: 36879663 PMC: 9985165. DOI: 10.1093/noajnl/vdac181.

Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma.

Takashima Y, Hamano M, Yoshii K, Hayano A, Fukai J, Iwadate Y Int J Clin Oncol. 2023; 28(3):468-481.

PMID: 36607476 DOI: 10.1007/s10147-022-02285-8.

COVID-19 Specific Immune Markers Revealed by Single Cell Phenotypic Profiling.

Sansico F, Miroballo M, Bianco D, Tamiro F, Colucci M, De Santis E Biomedicines. 2021; 9(12).

PMID: 34944610 PMC: 8698462. DOI: 10.3390/biomedicines9121794.

Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.

Takashima Y, Kawaguchi A, Fukai J, Iwadate Y, Kajiwara K, Hondoh H PLoS One. 2021; 16(6):e0251272.

PMID: 34166375 PMC: 8224980. DOI: 10.1371/journal.pone.0251272.

References

Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J . Primary brain tumours in adults. Lancet. 2012; 379(9830):1984-96. DOI: 10.1016/S0140-6736(11)61346-9. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Goecke I, Alvarez C, Henriquez J, Salas K, Molina M, Ferreira A . Methotrexate regulates the expression of glucocorticoid receptor alpha and beta isoforms in normal human peripheral mononuclear cells and human lymphocyte cell lines in vitro. Mol Immunol. 2006; 44(8):2115-23. DOI: 10.1016/j.molimm.2006.07.303. View

Rushworth D, Mathews A, Alpert A, Cooper L . Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation. J Biol Chem. 2015; 290(38):22970-6. PMC: 4645590. DOI: 10.1074/jbc.C115.671123. View

Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H . First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol. 2015; 26(7):1305-13. PMC: 4735103. DOI: 10.1093/annonc/mdv076. View

Reni M, Ferreri A, Villa E . Second-line treatment for primary central nervous system lymphoma. Br J Cancer. 1999; 79(3-4):530-4. PMC: 2362452. DOI: 10.1038/sj.bjc.6690083. View

Mattaini K, Sullivan M, Vander Heiden M . The importance of serine metabolism in cancer. J Cell Biol. 2016; 214(3):249-57. PMC: 4970329. DOI: 10.1083/jcb.201604085. View

Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino J . Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med. 1996; 335(14):1041-8. DOI: 10.1056/NEJM199610033351408. View

Zhao R, Goldman I . Resistance to antifolates. Oncogene. 2003; 22(47):7431-57. DOI: 10.1038/sj.onc.1206946. View

10.

Walling J . From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs. 2005; 24(1):37-77. DOI: 10.1007/s10637-005-4541-1. View

11.

Jin G, Huang J, Hu Z, Dai J, Tang R, Chen Y . Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population. Cancer. 2010; 116(24):5700-9. DOI: 10.1002/cncr.25301. View

12.

Hayano A, Takashima Y, Yamanaka R . Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. Int J Clin Oncol. 2019; 24(9):1020-1029. DOI: 10.1007/s10147-019-01451-9. View

13.

Takashima Y, Yoshimura T, Kano Y, Hayano A, Hondoh H, Ikenaka K . Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells. BMC Cancer. 2019; 19(1):910. PMC: 6739943. DOI: 10.1186/s12885-019-6129-8. View

14.

Chang C, Lin C, Cheng A, Medeiros L, Chang K . Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology. 2015; 67(5):625-35. DOI: 10.1111/his.12706. View

15.

Braggio E, Van Wier S, Ojha J, McPhail E, Asmann Y, Egan J . Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res. 2015; 21(17):3986-94. PMC: 4558226. DOI: 10.1158/1078-0432.CCR-14-2116. View

16.

Zorofchian S, Lu G, Zhu J, Duose D, Windham J, Esquenazi Y . Detection of the p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma. Front Oncol. 2018; 8:382. PMC: 6158312. DOI: 10.3389/fonc.2018.00382. View

17.

Takahashi Y, Sawada T, Akahane T, Kawase Y, Ikeda H, Makino K . Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma. Oncol Lett. 2017; 14(1):264-270. PMC: 5494900. DOI: 10.3892/ol.2017.6122. View

18.

Rubenstein J, Geng H, Fraser E, Formaker P, Chen L, Sharma J . Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018; 2(13):1595-1607. PMC: 6039666. DOI: 10.1182/bloodadvances.2017014845. View

19.

Takashima Y, Sasaki Y, Hayano A, Homma J, Fukai J, Iwadate Y . Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. Oncotarget. 2018; 9(44):27471-27486. PMC: 6007945. DOI: 10.18632/oncotarget.25463. View

20.

Hayano A, Komohara Y, Takashima Y, Takeya H, Homma J, Fukai J . Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. Anticancer Res. 2017; 37(10):5655-5666. DOI: 10.21873/anticanres.12001. View